Search results for: Biologics

ACR Scores Wins for Rheumatology Community at AMA House of Delegates Interim Meeting

From the College | November 17, 2022

Key successes for the rheumatology community secured by the ACR’s delegation include passage of the ACR’s resolution addressing pharmacy benefit administrators, advances in policies to protect rheumatologists and patients in the post-Dobbs landscape and retention of the rheumatology’s representation in the AMA House of Delegates.

FDA Approves Ustekinumab for Children with PsA

Michele B. Kaufman, PharmD, BCGP | November 7, 2022

After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.

ACR Leads AMA Resolution to Address Disruptive Practices of Pharmacy Benefit Administrators

From the College | October 24, 2022

At the AMA House of Delegates meeting in November, the ACR’s delegation will lead over a dozen cosponsoring specialties and medical associations in advancing a resolution addressing serious concerns about third-party pharmacy benefit administrators and the impacts of their disruptive practices.

Changing Treatment Patterns for Patients with JIA

Lara C. Pullen, PhD | October 18, 2022

A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.

Clinical Academic Rheumatology Generates Profits for Health Systems

Lara C. Pullen, PhD | October 11, 2022

Rheumatologists should be better compensated, in part, due to the revenue they bring to the hospital system from their procedures, argue D’Anna et al., who found that clinical academic rheumatologists bring significant downstream revenue to the healthcare system.

Belimumab Promising for Children with Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP | October 6, 2022

Belimumab is now FDA approved to treat children aged 5 years and older with active lupus nephritis, providing treatment options for pediatric patients at risk of developing renal damage.

Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

Ruth Jessen Hickman, MD | September 13, 2022

The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case

Richard D. Sontheimer, MD, & Samantha C. Shapiro, MD | September 5, 2022

As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…

Cliff Diving: Evergreening & Other Oddities

Philip Seo, MD, MHS | September 5, 2022

The glassblowers were in revolt. The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean,…

September Updates from the ACR Insurance Subcommittee

Rebecca Shepherd, MD, MBA, FACR, FACP | September 3, 2022

In recent months, the ISC has engaged with payers to reduce administrative burden on practices and continues to advocate to the CMS for the use of complex administration codes for biologics.